Nordic Issuing

Ongoing case

Pharmiva AB

Back to all cases

Pharmiva AB

12 Sep - 26 Sep 2022Rights issue

Pharmiva is a Swedish femtech company that works for better vaginal health by developing innovative antibiotic-free treatments against vaginal infections.

The company’s first product is Vernivia®, a non-prescription CE-certified vaginal mousse with the indication bacterial vaginosis (BV), a common vaginal infection that affects 1 in 3 women aged 14-49. With Vernivia® vaginal mousse, women get access to an effective treatment that both cures the infection and provides rapid symptom relief without at the same time causing the problematic side effects that today’s antibiotic treatments mean for both the individual and global health with the serious development of antibiotic resistance. The launch of Vernivia®, which is sold via pharmacy chains in Sweden, is the first step towards Pharmiva’s goal of becoming a global femtech company with a broad portfolio of antibiotic-free products in vaginal health. Pharmiva’s employees together have broad Life Science experience and knowledge in the field of therapy and product development.

Read more at the company's website

The offer in summary

Record date: 7 September 2022

Subscription period: 12 September - 26 September 2022

Subscription rights: Anyone who is a shareholder in the Company on the record date of September 7, 2022 has preferential rights to subscribe for shares in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) subscription right. Three (3) subscription rights entitle the holder to subscribe for two (2) new shares.

Price: 1.80 SEK

The offer: 5 489 648 shares

Trading with rights: 12 September - 21 September 2022

Market place: Nasdaq First North Growth Market

Financial advisor: Sedermera Corporate Finance


  Money laundering form


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.